Panitumumab first-line CRC trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amgen/Abgenix initiate a Phase III trial of the epidermal growth factor receptor antagonist panitumumab in first-line metastatic colorectal cancer, the firms announce April 26. The open-label PACCE (Panitumumab Advanced Colorectal Cancer Evaluation) trial will randomize 1,000 patients to receive panitumumab on top of either an oxaliplatin- (Sanofi-Aventis' Eloxatin) or irinotecan-based (Pfizer's Camptosar) regimen. Amgen is also preparing to submit an application in the second half of 2005 for panitumumab's use in third-line CRC (1Pharmaceutical Approvals Monthly April 2005, In Brief)...